Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.51 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.45 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.44 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL28330086 | 1.00 | LMNA (0.53) | LMNAALDH1A1RAB9AMAPTMEN1 | |
| SCHEMBL658053 | 0.98 | LMNA (0.54) | LMNAALDH1A1RAB9AMAPTMEN1 | |
| Hydrochloric Acid SCHEMBL8015558 | 0.93 | MEN1 (0.48) | LMNAALDH1A1RAB9AMAPTMEN1 | |
| Sulfur Dioxide SCHEMBL28176580 | 0.92 | LMNA (0.50) | LMNAALDH1A1RAB9AMAPTMEN1 | |
| SCHEMBL460030 | 0.91 | ALDH1A1 (0.49) | LMNAALDH1A1RAB9AMAPTMEN1 | |
| Sulfuric Acid SCHEMBL5004844 | 0.91 | ALDH1A1 (0.49) | LMNAALDH1A1RAB9AMAPTMEN1 | |
| SCHEMBL11650926 | 0.88 | ALDH1A1 (0.47) | LMNAALDH1A1RAB9AMAPTMEN1 | |
| SCHEMBL28161510 | 0.88 | ALDH1A1 (0.47) | LMNAALDH1A1RAB9AMAPTMEN1 | |
| Nitric Acid SCHEMBL27965091 | 0.88 | ALDH1A1 (0.47) | LMNAALDH1A1RAB9AMAPTMEN1 | |
| Cadaverine Tartrate SCHEMBL28296884 | 0.88 | MAPT (0.47) | LMNAALDH1A1RAB9AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 596 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119431172-A | Production method of L-phenylglycine methyl ester hydrochloride | 山东优盈新材料有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-115851786-B | Gene for encoding penicillin G acylase and application of expressed mutated penicillin G acylase in preparation of cephalexin | 河北凯恩利生物技术有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-115340503-B | Synthesis method and application of chiral semicorrinoid compound | 四川师范大学 | 2024-12-24 | — | — | CN | claimed |
| CN-118516440-A | Method for synthesizing cefaclor by catalyzing immobilized penicillin G acylase | 珠海联邦制药股份有限公司 | 2024-08-20 | — | — | CN | claimed |
| CN-115058479-B | Method for preparing high-purity cefaclor through enzymatic reaction crystallization | 河北工业大学 | 2024-06-28 | — | — | CN | claimed |
| CN-117947137-A | Penicillin amidase for synthesizing cefaclor | 上海康鑫化工有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-115232130-B | APN and AKT double-target inhibitor and preparation method and application thereof | 山东大学 | 2024-01-12 | — | — | CN | claimed |
| CN-116678969-A | Analysis method of L-phenylglycine methyl ester hydrochloride | 华北制药股份有限公司 | 2023-09-01 | — | — | CN | claimed |
| CN-115851786-A | Gene for coding penicillin G acylase and application of expressed mutated penicillin G acylase in preparation of cefalexin | 河北凯恩利生物技术有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-115340503-A | Synthetic method and application of chiral hemicorrin compound | 四川师范大学 | 2022-11-15 | — | — | CN | claimed |
| CN-105274177-A | Preparation method of cephalexin raw material and capsules | NCPC HEBEI HUAMIN PHARMACEUTICAL CO LTD | 2016-01-27 | — | — | CN | claimed |
| CN-104974164-A | Preparation method of 6-aminomethyl-6, 11-dihydro-5H-dibenzo [ b, e ] azepine | UNIV DALIAN TECH | 2015-10-14 | — | — | CN | claimed |
| CN-103805671-B | A kind of method preparing Cephalexin Monohydrate Micro/Compacted | NCPC HEBEI HUAMIN PHARMA CO., LTD. (CN) | 2015-08-26 | — | — | CN | claimed |
| CN-104726528-A | Ampicillin preparation technology by direct method | Inner mongolia changsheng pharmaceutical co ltd | 2015-06-24 | — | — | CN | claimed |
| CN-104120120-A | Immobilized recombinant penicillin G acylase and application thereof | UNIV ZHEJIANG TECHNOLOGY | 2014-10-29 | — | — | CN | claimed |
| CN-103805672-A | Technology for preparing ampicillin by adopting enzymic method | NORTH CHINA PHARMACEUTICAL GROUP SEMISYNTECH CO LTD | 2014-05-21 | — | — | CN | claimed |
| CN-103805671-A | Method for preparing cefalexin | NCPC HEBEI HUAMIN PHARMACEUTICAL CO LTD | 2014-05-21 | — | — | CN | claimed |
| CN-102320986-A | Preparation method for clopidogrel intermediate | WUHAN WUYAO TECHNOLOGY CO LTD | 2012-01-18 | — | — | CN | claimed |
| US-20100145070-A1 | ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-06-10 | — | — | US | claimed |
| CN-101723826-A | Preparation method of trans-D-chrysanthemic acid | SHENYANG XINYUANQUAN CHEMICAL | 2010-06-09 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100145070-A1 | ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF | DCK, DHPS, DHX15 | AGTR1 2761/4885CA2 3718/4885GAA 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.